RU2016150116A - Ингибитор пролиферации раковых стволовых клеток - Google Patents
Ингибитор пролиферации раковых стволовых клеток Download PDFInfo
- Publication number
- RU2016150116A RU2016150116A RU2016150116A RU2016150116A RU2016150116A RU 2016150116 A RU2016150116 A RU 2016150116A RU 2016150116 A RU2016150116 A RU 2016150116A RU 2016150116 A RU2016150116 A RU 2016150116A RU 2016150116 A RU2016150116 A RU 2016150116A
- Authority
- RU
- Russia
- Prior art keywords
- stem cell
- cancer stem
- cell growth
- agonist
- inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 7
- 201000011510 cancer Diseases 0.000 title claims 7
- 210000000130 stem cell Anatomy 0.000 title claims 7
- 239000003112 inhibitor Substances 0.000 title claims 4
- 239000000556 agonist Substances 0.000 claims 6
- 230000010261 cell growth Effects 0.000 claims 6
- 239000003966 growth inhibitor Substances 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical group CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001973 epigenetic effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (6)
1. Ингибитор роста раковых стволовых клеток, включающий ретиноидный агонист, представляющий собой тамибаротен (Am-80) в качестве эффективного компонента.
2. Ингибитор роста раковых стволовых клеток по п. п.1, дополнительно включающий рексиноидный агонист в качестве эффективного компонента.
3. Ингибитор роста раковых стволовых клеток по п. 2, где указанным рексиноидным агонистом является бексаротен.
4. Ингибитор роста раковых стволовых клеток по любому из пп. 1-3, включающий противораковое лекарственное средство.
5. Ингибитор роста раковых стволовых клеток по п. 4, где указанный ретиноидный агонист содержится в количестве от 0,5 до 20 мг на человеческий индивидуум; где указанный ретиноидный агонист и указанный рексиноидный агонист содержатся в общем количестве от 0,5 до 500 мг на человеческий индивидуум; и где указанное противораковое лекарственное средство содержится в количестве от 1,0 до 1000 мг на человеческий индивидуум.
6. Ингибитор роста раковых стволовых клеток по п. 4 или 5, где указанное противораковое лекарственное средство выбрано из группы, состоящей из агентов, взаимодействующих с ДНК; антиметаболитов; агентов, взаимодействующих с тубулином; молекулярно-направленных терапевтических агентов, ингибиторов эпигенетического действия, и гормонов.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014105543 | 2014-05-21 | ||
| JP2014-105543 | 2014-05-21 | ||
| PCT/JP2015/064523 WO2015178426A1 (ja) | 2014-05-21 | 2015-05-20 | がん幹細胞の増殖抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016150116A true RU2016150116A (ru) | 2018-06-22 |
| RU2016150116A3 RU2016150116A3 (ru) | 2018-09-25 |
Family
ID=54554092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016150116A RU2016150116A (ru) | 2014-05-21 | 2015-05-20 | Ингибитор пролиферации раковых стволовых клеток |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170079942A1 (ru) |
| EP (1) | EP3146978B1 (ru) |
| JP (1) | JPWO2015178426A1 (ru) |
| KR (1) | KR20170005069A (ru) |
| CN (2) | CN114392252A (ru) |
| AU (1) | AU2015262349A1 (ru) |
| CA (1) | CA2949640A1 (ru) |
| ES (1) | ES2928499T3 (ru) |
| MX (1) | MX2016015092A (ru) |
| RU (1) | RU2016150116A (ru) |
| TW (1) | TW201607531A (ru) |
| WO (1) | WO2015178426A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014145295A1 (en) | 2013-03-15 | 2014-09-18 | Avisenna Cosmetics, Llc | Topical compositions for reducing aging effects |
| EP3560494A4 (en) * | 2016-12-20 | 2020-08-05 | Sumitomo Dainippon Pharma Co., Ltd. | MEDICINAL PRODUCT TARGETING A CARCINOUS STEM CELL |
| IT201800005072A1 (it) * | 2018-05-04 | 2019-11-04 | Nuovi farmaci prosenescenza | |
| RU2702910C2 (ru) * | 2018-12-20 | 2019-10-14 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения количества стволовых клеток рака молочной железы |
| RU2700695C2 (ru) * | 2019-02-27 | 2019-09-19 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения клоногенной активности стволовых клеток рака молочной железы |
| US20230301950A1 (en) * | 2020-06-26 | 2023-09-28 | Raqualia Pharma Inc. | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
| EP4274562A1 (en) * | 2021-01-08 | 2023-11-15 | Syros Pharmaceuticals, Inc. | Treatment regimens with fixed doses of tamibarotene |
| CN114045259B (zh) * | 2021-11-08 | 2024-04-05 | 山东第一医科大学(山东省医学科学院) | 一种抑制肿瘤干细胞的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006279400A1 (en) * | 2005-08-18 | 2007-02-22 | Merck & Co. Inc. | Combination methods of SAHA and Targretin for treating cancer |
| ES2395401T3 (es) * | 2006-03-23 | 2013-02-12 | Tmrc Co., Ltd. | kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer |
-
2015
- 2015-05-20 RU RU2016150116A patent/RU2016150116A/ru not_active Application Discontinuation
- 2015-05-20 CN CN202210166733.7A patent/CN114392252A/zh active Pending
- 2015-05-20 ES ES15796913T patent/ES2928499T3/es active Active
- 2015-05-20 WO PCT/JP2015/064523 patent/WO2015178426A1/ja active Application Filing
- 2015-05-20 KR KR1020167034364A patent/KR20170005069A/ko unknown
- 2015-05-20 CN CN201580025982.2A patent/CN106456770A/zh active Pending
- 2015-05-20 US US15/312,484 patent/US20170079942A1/en not_active Abandoned
- 2015-05-20 AU AU2015262349A patent/AU2015262349A1/en not_active Abandoned
- 2015-05-20 CA CA2949640A patent/CA2949640A1/en not_active Abandoned
- 2015-05-20 EP EP15796913.0A patent/EP3146978B1/en active Active
- 2015-05-20 JP JP2016521132A patent/JPWO2015178426A1/ja active Pending
- 2015-05-20 MX MX2016015092A patent/MX2016015092A/es unknown
- 2015-05-21 TW TW104116251A patent/TW201607531A/zh unknown
-
2019
- 2019-11-04 US US16/672,783 patent/US20200061007A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3146978A1 (en) | 2017-03-29 |
| EP3146978B1 (en) | 2022-07-20 |
| AU2015262349A1 (en) | 2017-02-02 |
| JPWO2015178426A1 (ja) | 2017-04-20 |
| US20170079942A1 (en) | 2017-03-23 |
| CN114392252A (zh) | 2022-04-26 |
| ES2928499T3 (es) | 2022-11-18 |
| CN106456770A (zh) | 2017-02-22 |
| WO2015178426A1 (ja) | 2015-11-26 |
| KR20170005069A (ko) | 2017-01-11 |
| CA2949640A1 (en) | 2015-11-26 |
| TW201607531A (zh) | 2016-03-01 |
| EP3146978A4 (en) | 2017-12-20 |
| US20200061007A1 (en) | 2020-02-27 |
| MX2016015092A (es) | 2017-05-09 |
| RU2016150116A3 (ru) | 2018-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016150116A (ru) | Ингибитор пролиферации раковых стволовых клеток | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| EP3173092A3 (en) | Rna containing composition for treatment of tumor diseases | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| WO2015023976A3 (en) | Selective grp94 inhibitors and uses thereof | |
| WO2016044189A8 (en) | Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists | |
| WO2015153959A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
| EP3862362A3 (en) | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression | |
| EA201591792A1 (ru) | Улучшенные композиции для лечения мышечной дистрофии | |
| WO2015195848A8 (en) | Ezh2 inhibitors for treating lymphoma | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| WO2015011694A3 (en) | Isotopologues of smad7 antisense oligonucleotides | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| WO2015100113A3 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
| WO2015188198A3 (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta | |
| EP3209143A4 (en) | Feeding algae to cattle at low doses to produce high omega 3 levels in beef | |
| EA201692371A1 (ru) | 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений | |
| CL2015001397A1 (es) | Compuestos derivados de 4-amino-7,8-dihidropirimido[5,4-f][1,4]oxazepin-5(6h)-ona, inhibidores de diacilglicerol aciltransferasa; composicion farmaceutica y el uso en el tratamiento de la obesidad. | |
| Kwon et al. | The TRAIL Sensitization Effect of Substituted Triazolyl Curcumin Mimics Against Brain Cancer Cells. | |
| WO2015114633A8 (en) | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190218 |